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Summary
Background Routinely collected electronic health data obtained for administrative
and clinical purposes are increasingly used to study atopic dermatitis (AD). Meth-
ods for identifying AD patients in routinely collected electronic health data differ,
and it is unknown how this might affect study results.
Objectives To evaluate how patients with AD have been identified in studies using
routinely collected electronic health data, to determine whether these methods
were validated and to estimate how the method for identifying patients with AD
affected variability in prevalence estimates.
Methods We systematically searched PubMed, Embase and Web of Science for stud-
ies using routinely collected electronic health data that reported on AD as a primary
outcome. Studies of localized AD and other types of dermatitis were excluded. The
protocol for this review was registered in PROSPERO (CRD42016037968).
Results In total, 59 studies met eligibility criteria. Medical diagnosis codes for
inclusion and exclusion, number of occasions of a code, type of provider associ-
ated with a code and prescription data were used to identify patients with AD.
Only two studies described validation of their methods and no study reported on
disease severity. Prevalence estimates ranged from 018% to 3833% (median
491%) and up to threefold variation in prevalence was introduced by differences
in the method for identifying patients with AD.
Conclusions This systematic review highlights the need for clear reporting of meth-
ods for identifying patients with AD in routinely collected electronic health data
to allow for meaningful interpretation and comparison of results.
What’s already known about this topic?
• Increasingly, studies are using routinely collected data to study atopic dermatitis (AD).
• It is unclear how patients with AD are identified and whether methodological dif-
ferences could have an impact on study findings.
What does this study add?
• We performed a systematic review of methods for identifying patients with AD in
studies using routinely collected data and found differences in methods were asso-
ciated with up to a threefold variation in prevalence estimates.
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• We found variability in methods associated with up to a threefold variation in
prevalence estimates.
• We encourage validation of methods and offer suggestions for reporting to allow
for meaningful interpretation and comparison of results.
Atopic dermatitis (AD, also known as eczema or atopic eczema)
affects both children and adults, and increasing data suggest it is
a systemic inflammatory disease.1 There is an unmet need for
additional research in large, representative populations with
longitudinal follow-up and data on comorbid conditions. ‘Rou-
tinely collected’ electronic health data obtained for administra-
tive and clinical purposes often meet these criteria and are
increasingly being used to study the epidemiology, natural his-
tory and association of AD with other diseases.2 They could
include data for clinical management (e.g. primary care data-
bases), health system planning (e.g. health administrative data),
documentation of clinical care (e.g. electronic health record data
repositories) or epidemiological surveillance (e.g. cancer reg-
istries and public health reporting data). Because these data are
not generated specifically for research purposes, they require
careful validation to ensure accuracy and reproducibility.2
Unlike some conditions for which diagnosis may be based on
diagnostic tests or laboratory values easily retrievable from med-
ical records, AD diagnosis is typically based solely on clinical
signs and symptoms, and physician assessment is considered the
‘gold standard’.3–5 Moreover, AD is clinically heterogeneous,
with variable morphology, severity and clinical course, all of
which can present challenges to identifying patients with AD
accurately in routinely collected health data. It is possible that
AD prevalence and severity estimates are influenced by the
method used to identify patients. Therefore, we aimed to pro-
vide an overview of AD disease definition in studies using rou-
tinely collected data. The primary objectives of this systematic
review were to evaluate how patients with AD have been identi-
fied and how disease severity was defined. We also aimed to
determine whether these methods were validated (i.e. whether
any information was included about the accuracy of methods
for identifying AD) and, when applicable, to estimate how AD
disease definitions affected the variability in AD prevalence.
Materials and methods
The review protocol was registered in PROSPERO, (CRD42016
037968, http://www.crd.york.ac.uk/PROSPERO). We followed
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) and Reporting of studies Conducted Using
Observational Routinely collected Data (RECORD) guidelines,
which are an extension of the STROBE guidelines.2,6,7
Types of studies
We included cohort, case–control and cross-sectional studies
using routinely collected health data reporting on AD as a
primary outcome. Studies that examined AD as a predictor of a
separate outcome (e.g. cancer diagnosis) were not included.
Routinely collected health data were defined as data collected
without specific a priori research questions and developed
prior to utilization for research.2 Data sources designed to
investigate specific questions about AD or atopic diseases, such
as the International Study of Asthma and Allergies in Child-
hood (ISAAC), birth cohorts of patients with AD, and registries
of patients with AD, were excluded. Studies of localized AD,
such as hand eczema or other types of dermatitis such as con-
tact dermatitis and seborrhoeic dermatitis, were also excluded.
Outcome
Our primary end point was the criteria used to identify patients
with AD in each study. We also examined whether these crite-
ria were validated (i.e. whether any information was included
about the accuracy of methods for identifying AD), how dis-
ease severity was defined and the prevalence of AD.
Search strategy
With the help of a professional librarian, we searched MED-
LINE via PubMed, Embase and Web of Science for studies
indexed until 10 April 2016. Table S1 (see Supporting Infor-
mation) shows the detailed search strategy. Studies in any lan-
guage were included. Because the focus of this review was to
describe how AD has been defined in the mainstream pub-
lished literature, we excluded literature reviews, abstracts, con-
ference proceedings, unpublished studies, ongoing studies and
the grey literature (i.e. reports and research disseminated out-
side of commercial publishing). We cross-referenced review
articles and reference lists to ensure completeness.
Selection and data extraction
Three authors (M.P.D. and one of A.M.Y., R.K.S.) performed
the study selection independently and in duplicate. Titles and
abstracts were screened for inclusion, followed by a full-text
review if abstracts were insufficient to determine whether
studies met inclusion or exclusion criteria. Discrepancies were
resolved through discussion and consensus with additional
authors (K.A. and S.M.L.). For each eligible study, we
extracted information on the database used, country of study,
study objective, patient demographics, features of algorithms
used to identify individuals with AD and prevalence estimates.
When possible, missing data, including specific diagnosis
codes, were obtained by contacting the study author(s).
© 2018 The Authors. British Journal of Dermatology
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Data synthesis and analysis
We described the characteristics of relevant studies. Features
of algorithms used to identify individuals with AD were tabu-
lated for the included studies, and the median prevalence and
variability (interquartile range and ratio of 75th to 25th per-
centile) were calculated by subgroup. We also reported the
proportion of studies in which these algorithms have been
validated and described the methods of validation.
Risk of bias
Systematic reviews often include an assessment of the risk of
bias. This involves rating each included study on the methods
used for selection of the study groups, comparability of
groups and ascertainment of exposure and outcome.6,8 These
categorizations were not applicable to the objective of our
study (i.e. we focused exclusively on how an outcome, AD,
was defined), so no risk of bias assessment was performed.
Results
Selection and characteristics of studies
Our search identified 1354 studies. Title and abstract review
identified 127 articles for the full-text review. Of these, 68
were excluded and 59 met the inclusion criteria (Fig. 1).
Table 1 shows the characteristics of the included studies. The
vast majority of studies (90%) included children; only six
studies (10%) included only adults. Most studies (81%)
included both male and female patients, 61% were from
North America or Europe, and the remainder came from East
Asia. The included studies were published between 1994 and
2016, and data came from the years 1967–2014. Most stud-
ies (58%) were conducted using administrative databases
(e.g. insurance databases, birth/death registries or employ-
ment registries). Primary care databases, national patient reg-
isters, institutional electronic medical records and hybrid
databases compiling information from multiple sources were
also used.
Algorithm features
We categorized algorithms that were used to identify patients
with AD into: (i) diagnosis codes, (ii) number of occasions of
a code, (iii) type of provider associated with a code, and (iv)
prescription data.
Diagnosis codes
Multiple codes from multiple coding systems, including Inter-
national Statistical Classification of Diseases and Related Health
Problems (ICD)-9/10 and Read/OXMIS, were used. We
grouped studies into those that used codes specifically for AD,
and those that used codes referring to a broader group of der-
matitis-related disorders (including, for example, contact der-
matitis and eczema not otherwise specified) (Table S2; see
Supporting Information). When we compared the terminology
Citations identified through electronic databases search (n = 1354)
• MEDLINE (n = 658)
• Embase (n = 562)
• Web of Science (n = 134)
Exclude duplicates  (n = 282)
Screening of titles and abstracts (n = 1072)
Exclude after reviewing titles and abstracts (n = 945)
Excluded  (n = 68)
• Not related to clinical eczema (n = 1)
• Not routinely collected data (n = 22)
• Eczema is not a primary outcome (n = 6)
• Did not use diagnosis codes (n = 14)
• Abstract (n = 17)
• Authors contacted and codes were not available (n = 8)
Studies that met inclusion criteria (n = 59)
Full-text assessed for eligibility  (n = 127)
Fig 1. Flow diagram.
© 2018 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2018) 178, pp1280–1287
1282 AD definitions in studies using routinely collected health data, M.P. Dizon et al.
used in each published study (i.e. ‘atopic dermatitis’ vs.
‘eczema’) to the types of codes, we found imperfect overlap
(Table 2). Only one study directly incorporated codes for exclu-
sionary diagnoses (‘diaper or napkin rash’ and ‘contact dermati-
tis and other eczema’) as part of their algorithm for AD.9
Number of occasions of a code
A total of 10 studies used algorithms that required multiple
instances of codes to identify patients as having AD. Two stud-
ies10,11 used unique algorithms that identified individuals if
they had at least one inpatient claim or two outpatient claims
associated with diagnosis codes for AD. Nine studies specified
codes associated with AD must occur on a minimum of two
occasions,12–20 and one study required three medical visits
coded for AD to identify patients.21
Type of provider associated with a code
A total of seven studies, all of which were conducted in Tai-
wan using the National Health Insurance Research Database,
specified the type of provider required to enter a diagnosis to
define an individual with AD. Three studies required a diagno-
sis by a dermatologist,14,17,22 three studies required a diagno-
sis by a dermatologist or a paediatrician15,23,24 and one study
required a diagnosis by a ‘specialist.’18
Prescription data
Five studies included medication prescriptions in the algo-
rithms used to identify patients with AD. One study required
a patient to have a diagnosis code and a recorded prescription
of a treatment for AD (e.g. emollients, topical corticosteroids
and topical calcineurin inhibitors).25 Two studies specified
diagnosis either by diagnosis code or a prescription for cal-
cineurin inhibitors or topical corticosteroids26,27 and one
study used only prescription codes for either topical corticos-
teroids or topical calcineurin inhibitors to identify patients
with eczema.28
Validation information
Only two studies described methods to validate the algorithms
used to identify individuals with AD. The first study assessed
the validity of ICD-9-CM codes by conducting a detailed chart
review of randomly selected visits of 1000 patients.29 The
ICD-9-CM diagnosis was confirmed in 93% of cases; however,
the study included a range of skin diseases and was not lim-
ited to AD. The criteria used in the chart review to confirm
diagnoses were not described. The second study calculated the
positive predictive value of filled prescriptions of topical corti-
costeroids or immunosuppressants for identifying patients
with an ‘umbrella diagnosis’ of dermatitis or eczema based on
diagnosis codes, and found positive predictive values of 82%
and 45%, respectively.30 The study described specific clinical
criteria used to validate asthma diagnoses in a subset of paedi-
atric patients through review of medical records; however,
coded diagnoses for dermatitis and eczema were not evaluated
against clinical criteria.
Table 1 Characteristics of the included studies
n (%)
Age groups included in study sample
Children 32 (54)
Adults 6 (10)
Both 21 (36)
Sex of patients included in study sample
Male only 4 (7)
Female only 0
Both male and female 48 (81)
Not reported 7 (12)
Countries represented in studiesa
Taiwan 19
South Korea 2
U.S.A. 7
Canada 1
Sweden 5
Denmark 3
Norway 1
Finland 1
U.K. 11
The Netherlands 4
Germany 4
Australia 2
Type of routinely collected datab
National patient register 3 (5)
Administrative databases (insurance,
birth/death, employment)
34 (58)
Primary care databases 15 (25)
Institution-specific electronic medical record 3 (5)
Hybridb 4 (7)
Provided an estimate of atopic dermatitis prevalence
Yes 40 (68)
No 19 (32)
aFor some studies, data came from more than one country; bhy-
brid datasets included patient data from sources spanning multi-
ple categories (i.e. both primary care databases and
administrative databases). National patient registers include hos-
pital records in countries with government-funded universal
healthcare. They are not specific to insurance claims or prescrip-
tions nor are they limited to primary care.
Table 2 Comparison of manuscript terminology and medical codes
Terms used in
manuscript Total
Atopic
dermatitis
codes onlya
Atopic dermatitis
plus other dermatitis
codesa
Atopic dermatitis 31 26 (84) 5 (16)
Atopic
dermatitis/eczema
3 0 3 (100)
Atopic eczema 5 5 (100) 0
Dermatitis/eczema 3 0 3 (100)
Eczema 17 4 (24) 13 (76)
Variables are n (%). aA full listing of codes is detailed in
Table S2 (see Supporting Information).
© 2018 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2018) 178, pp1280–1287
AD definitions in studies using routinely collected health data, M.P. Dizon et al. 1283
Severity information
None of the studies included in the review reported on the
severity of AD within the study population.
Variation in prevalence estimates
Of the 59 included studies, 40 (68%) provided a prevalence
estimate of AD, which ranged from 018% to 3833%. Esti-
mates varied by features used to identify patients with AD,
study characteristics and the duration of time used to calculate
the period prevalence. Of note, the variation in prevalence
introduced by differences in the methods used to identify
patients was similar in magnitude to the variation in preva-
lence introduced by study characteristics (e.g. prevalence in
studies where the algorithm included prescription data was
169% vs. no prescription data at 45%; prevalence among
studies including children only was 11% vs. adults and/or
children at 4%, Table 3).
Studies that used only diagnosis codes specific to AD to
identify patients found a lower median prevalence than studies
that used more general dermatitis codes (43% vs. 115%),
and the amount of variability was similar (ratio of 75th to
25th percentile 31 vs. 33). Studies that required patients to
have specified diagnosis codes on multiple occasions found a
lower median prevalence (43% vs. 56%) and less variability
(ratio of 75th to 25th percentile 15 vs. 55) than studies that
only required one instance of a code. The same was true of
studies that required patients to have specified diagnosis codes
on multiple occasions vs. only one instance of a code found a
lower median prevalence (43% vs. 56%) and less variability
(ratio of 75th to 25th percentile 15 vs. 55). Finally, studies
that used prescription data to identify patients found a higher
median prevalence (169%, vs. 45%), versus studies that did
Table 3 Prevalence estimates by subgroup
Studies, n
Studies with
prevalence estimates, n Median prevalence, % IQR, %
Ratio of 75th to
25th percentile
Overall 59 40 491 264–1151 436
Features of algorithms used to identify AD patients
Diagnosis code category
Limited to AD 35 26 430 214–670 313
AD plus others 23 13 1153 920–3023 329
Algorithm included number of visits/codes
Required multiple occasions 8 8 427 385–561 146
No 50 31 560 224–1237 552
Algorithm specified the type of provider associated with a code
Yes 5 5 453 439–670 153
No 53 34 491 250–1150 460
Algorithm included prescription data
Yes 5 3 1693 1237–3249 263
No 54 37 453 250–1094 438
Study characteristics
Age of patient population
Children only 32 19 1094 469–1900 405
Adults +/ children 27 21 380 214–560 262
Continent
Europe 28 21 1035 380–1693 446
North America 8 4 605 285–905 318
Asia 21 15 439 221–670 303
Type of routinely collected data
National patient register 3 1 1237 n/a n/a
Administrative database 34 26 427 224–670 299
Primary care database 15 11 1324 279–3140 1125
Hybrid 4 2 681 442–920 208
Terminology
Atopic dermatitis 31 21 469 224–1094 488
Atopic dermatitis/eczema 3 2 285 250–320 128
Atopic eczema 5 4 385 225–713 317
Eczema 17 13 1150 442–3023 684
Prevalence calculation
Time period
1-year period prevalence 9 9 279 224–343 153
Multiyear period prevalence 29 29 890 415–1321 318
IQR, interquartile range; AD, atopic dermatitis; n/a; not applicable.
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not specify any restrictions on provider type possibly because
of misclassification of patients receiving medications for other
conditions.
Prevalence estimates also varied by region and age group,
with the median prevalence higher in studies that included
only children. The duration of period prevalence ranged from
1 to 39 years; among the nine estimates that calculated a 1-
year prevalence, the median prevalence was lower (28%)
than in studies that calculated a multiyear period prevalence
(89%).
Discussion
This review demonstrates variability in the way patients with
AD are identified in studies using routinely collected data. It
also highlights a lack of standardization in terminology, vali-
dation studies and information on disease severity, which are
all crucial to allow for comparison of study results. These
issues are not specific to AD; however, they are of particular
importance in AD because it is a common condition and mis-
classification of even a relatively small percentage of patients
could result in large absolute errors.
Much has been written about the inconsistent use of termi-
nology in allergic disorders, and efforts are under way to
improve the classification system and standardize terminology
used in coding.31–34 To ensure we captured all relevant stud-
ies, we used multiple terms in our search, including ‘atopic
dermatitis’, ‘dermatitis’, ‘eczema’ and other variants thereof
(Table S1; see Supporting Information). Inconsistent use of
terminology can be seen in Table 2, with some studies of
‘eczema’ including only patients with AD-specific diagnosis
codes and some studies of ‘atopic dermatitis’ including
patients with diagnosis codes for other types of inflammatory
skin conditions such as contact dermatitis. We found that use
of broader diagnosis codes increased the median prevalence
from 43% to 115% (Table 3). Such ‘lumping together’ of
different disease entities could inflate AD prevalence estimates,
although using more limited AD code sets might underesti-
mate the true prevalence. For example, a recent validation
study using electronic medical record data found that 42% of
patients with the nonspecific diagnosis code of 6929 and no
AD-specific code of 6918 had a final diagnosis of AD after
chart review.35 If a study focuses on more than one type of
dermatitis, authors should clearly delineate how each condi-
tion was defined, including which codes were used. Ideally,
studies examining multiple types of dermatitis would report
estimates separately by subgroups to facilitate comparison with
the existing literature.
This systematic review highlights the frequent use of nonva-
lidated algorithms to identify patients with AD in routinely
collected data; only two of 59 studies described any attempt
to validate the algorithms used. Validation research is a high
priority to ensure patients are accurately identified and avoid
misclassification bias,36 and since completion of our search
two new validation studies of AD using routinely collected
data have been published.35,37 Both highlighted the potential
magnitude of misclassification bias, even when using physi-
cian-defined codes. For example, using a single code for ‘ato-
pic dermatitis/eczema’, rather than one of five AD-related
codes in a primary care database from the U.K., could result
in a 50% reduction in prevalence estimates.38
The performance of coding algorithms for identifying
patients with AD is inherently context-specific. For example,
the performance of an algorithm may depend on the baseline
prevalence and the way in which diagnosis codes and phar-
macy codes are entered in a given setting. Moreover, in any
given context, the choice of coding algorithms may be related
to the goals of the study, as there is often a trade-off between
maximizing the number of true positives and reducing the
number of false positives, and the value of optimizing sensi-
tivity or specificity may depend on whether the study is aim-
ing to identify all possible cases or to identify only those with
definite disease. Therefore, each study should discuss evidence
for the validity of the methods used to identify patients with
AD.2 When possible, researchers also may consider showing
how changes in their definition of AD could affect their esti-
mates. Additional research is necessary to understand the gen-
eralizability of coding algorithms and the extent to which
these might be standardized across settings.
A secondary objective of this systematic review was to
examine methods used to describe AD severity in studies using
routinely collected electronic health data, however, none of
the studies meeting our inclusion criteria evaluated disease
severity. Current approaches to measuring AD severity are
often complex and not routinely documented in the medical
record39 or are not standardized,40 and therefore are difficult
to use in routinely collected electronic health data studies.
Treatment data and/or frequency of healthcare visits has been
used to define severity in studies of psoriasis and asthma using
routinely collected data and may be applicable to AD.41–44
Such an approach, if applied to AD, should be carefully
validated.
Strengths of this systematic review include a predefined and
registered protocol and adherence to reporting standards.6 We
included 59 studies of varying designs from a variety of set-
tings to show all of the ways patients with AD have been
defined in the literature to date. We included only studies
with AD as a primary outcome because we were most inter-
ested in whether differences in AD definitions would affect
prevalence estimates, but were unable to synthesize these esti-
mates using meta-analysis because of a lack of standardized
reporting of prevalence. Nonetheless, we include unadjusted
median and interquartile prevalence ranges, which demon-
strate variation in these estimates.
Clinicians should be aware that estimates from studies using
routinely collected data may vary depending on the algorithms
used to identify patients, and should be wary of studies that do
not provide data on the validity of these measures. The interna-
tional Harmonising Outcome Measures for Eczema (HOME)
initiative was founded in response to the lack of standardiza-
tion and validation of methods used to measure outcomes in
randomized clinical trials, and the initiative has resulted in
© 2018 The Authors. British Journal of Dermatology
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multiple publications suggesting standardized methods of mea-
surement and reporting.45–49 Similar international efforts are
needed for questionnaire-based studies and studies of AD using
routinely collected electronic health data. In the meantime, we
encourage authors to report on their methods clearly, includ-
ing: specific codes used to identify patients or exclude patients,
whether there was a minimum number of codes or visits
required, whether there were any restrictions on type of provi-
der associated with the code or visit, and whether prescription
data were used to identify patients. In addition, whenever pos-
sible, we encourage authors to report on the annual period
prevalence of visits and/or prescriptions for AD by age to
enable comparison across studies. All studies should include
information on the validity of the algorithm used in their par-
ticular locale and practice setting.
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